Indiana is currently home to 1217 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Recruiting
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or for whom there is no standard of care therapy as well as the safety, tolerability, preliminary efficacy, and immunologic effect of KB707 administered in combination... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: IU Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Recruiting
Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/14/2025
Locations: Indiana University Health University Hospital- Site Number : 127, Indianapolis, Indiana
Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema
HVLAT, Electric DN, Exercise Vs. Mobilization, STM, Exercise, TENS for Tension Type Headaches
Recruiting
The purpose of this research is to compare two different approaches for treating patients with tension-type headaches: thrust Manipulation, electric dry Needling and exercise Vs. non-thrust mobilization, soft-tissue mobilization, exercise and TENS. Physical therapists commonly use all of these techniques to treat tension-type headaches. This study is attempting to find out if one treatment strategy is more effective than the other.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/14/2025
Locations: Maller and Swoverland Orthopedic PT, Fort Wayne, Indiana
Conditions: Tension-Type Headache
Manual Therapy, Exercise and US Vs. Manual Therapy, Exercise and US for Medial Epicondylalgia
Recruiting
The purpose of this research is to compare two different approaches for treating patients with medial epicondylalgia: manual therapy, exercise and ultrasound and manual therapy, exercise, ultrasound and electric dry needling. Physical therapists commonly use all of these techniques to treat medial epicondylalgia. This study is attempting to find out if one treatment strategy is more effective than the other.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/14/2025
Locations: Mallers and Swoverland Orthopedic PT, Fort Wayne, Indiana
Conditions: Epicondylalgia
Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection
Recruiting
This study is being done to compare how well Zopocianine (OTL78) in combination with Near InfraRed (NIR) fluorescent imaging may improve the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Evaluating Tolerability of ePUHRT With Brachytherapy Boost
Recruiting
The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of internal radiation where a cancer doctor implants a small plastic tube or balloon (catheter) in the tumor).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Prostate Cancer
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
Recruiting
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/13/2025
Locations: The Indiana Clinical Trials Center PC, Plainfield, Indiana
Conditions: Prurigo Nodularis
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Recruiting
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/13/2025
Locations: Research Site, Elkhart, Indiana
Conditions: Heart Failure and Impaired Kidney Function
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: Indiana Hemophilia and Thrombosis Center- Site Number : 8400013, Indianapolis, Indiana
Conditions: Hemophilia A
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Franciscan Health Indianapolis, Indianapolis, Indiana
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Recruiting
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II V... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Research Site, Fort Wayne, Indiana
Conditions: Non-small Cell Lung Cancer